Scientific articles

1. Obesity related complications in children and adolescents

27% exhibit dyslipidemia (Appendix 1.1)

31% exhibit liver and 66% exhibit muscle steatosis (Appendix 1.2, ​Appendix 1.3​, Appendix 1.4, and Appendix 1.5)

50% exhibit pre- or overt hypertension (Appendix 1.6 and Appendix 1.7)

10,4% exhibit subclinical hypothyroidism (Appendix 1.8)

16,5% exhibit vitamin D deficiency (Appendix 1.9)

44 % exhibit sleep apnea (Appendix 1.10)

​

2. Treatment in the primary sector with the following effects:

74% of patients exhibit weight loss (Appendix 2.1)

Improvement of quality of life (Appendix 2.2)

Reduction in blood pressure (Appendix 2.3)

Reducing obesity and increasing quality of life, physical activity, mood, body perception and reducing appetite and bullying with the digital solution DrHolmApp (Appendix 2.4)

​

3. Treatment in the secondary sector with the following effects:

69% and 75% exhibit weight loss (Appendix 3.1 and Appendix 3.2)

Reduction in cholesterol levels (Appendix 3.3)

Reduction in blood pressure (Appendix 3.4 and Appendix 3.5)

Reduction of fatty liver and muscle fat (Appendix 3.6)

Improvement of quality of life (Appendix 3.7)

Weight loss in parents (Appendix 3.8)

Improvements in 9 out of 10 in cholesterol levels/degree of obesity/body composition (Appendix 3.9)

Equally effective treatment response despite familiar predispositions to obesity related comorbidities (Appendix 3.10)

Equally effective treatment response despite impaired glucose metabolism (Appendix 3.11)

Equally effective treatment response despite a genetic risk score composed of 15 commonly occurring with impact on development of obesity in children and youth (Appendix 3.12)

Same obesity treatment aproach regardless of disturbed eating behavior (Appendix 3.13)

Reduction of sleep apnea (Appendix 3.14)

Reducing obesity and increasing quality of life, physical activity, mood, body perception and reducing appetite and bullying with the digital solution DrHolmApp (Appendix 3.15)

​

Danish recommendations based on this method (Appendix 3A)

International recommendations for the treatment of youth with obesity (Appendix 3B)

​

4. Medication to children and adolescents with obesity

Patients with MC4R mutations are more difficult to treat (Appendix 4.1)

Patients with MC4R mutations (heterozygous) can be treated with medicine (Appendix 4.2)

Inconsistencies in dosage of medication in children and youth with obesity (Appendix 4.3)​

Patients with MC4R mutations (homozygous) can be treated with medicine (Appendix 4.4)

5. Genetic aspects of childhood obesity

Identification of 3 new genes with impact on obesity in children and youth (Appendix 5.1)

Genetic risk score describing insulin sensitivity, metabolic disease and altered fat distribution (Appendix 5.2)

Genetics and thyroid hormones (Appendix 5.3)

Genetics, birth weight and cardiovascular disease later in life (Appendix 5.4)

Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors (Appendix 5.5)

2 new genes (Appendix 5.6)

​

6. Pregnancy and early growth

Affected birth weight and length of pregnancy (Appendix 6.1)

Obesity related markers of gestational diabetes (Appendix 6.2)

Association between birth weight, degree of obesity, and body composition (Appendix 6.3 and Appendix 6.4)

PCOS and obesity (Appendix 6.5)

​

7. Other effects of childhood obesity

The gut microbiome can induce obesity (Appendix 7.1)

Physical activity in children and adolescents with obesity (Appendix 7.2)

Investigation of sensory-specific satiety (Appendix 7.3)

​

8. Markers of childhood obesity

Reference values for markers of obesity and comorbidities (Appendix 8.1, Appendix 8.2, and Appendix 8.3)

Changes in markers of obesity and comorbidities following obesity treatment (Appendix 8.4, Appendix 8.5, Appendix 8.6, and Appendix 8.7).

Relation between high blood glucose and comorbidities (Appendix 8.8 and Appendix 8.9)

​

9. Regarding obesity as a chronic disease and the lack of available treatment options

Position statement for declaring obesity as a chronic disease in Europe (Appendix 9.1)

Lack of available treatment clinics in Denmark (Appendix 9.2)​​

Proposal for new diagnostic criteria for obesity (Appendix 9.3)

​

10. Treatment and ethics

The ethics in childhood obesity treatment (Appendix 10.1)

​

11. COVID-19

Obesity and COVID-19 from The European Association (Appendix 11.1)

Obesity, COVID-19 and the immune system from The European Association (Appendix 11.2)